Core Viewpoint - XORTX Therapeutics Inc. has refilled its management's discussion and analysis (MD&A) for the financial year ended December 31, 2023, and the interim period ended June 30, 2024, following a review by the Alberta Securities Commission [1][2]. Group 1: Financial Reporting - The originally filed MD&A for the financial year ended December 31, 2023, included an abbreviated definition of Disclosure Controls and Procedures, which has now been amended to include the full definition as per NI 52-109 [2]. - The amended MD&A for the interim period ended June 30, 2024, provides additional information, including a breakdown of the use of funds for the Company's product candidates and estimated costs in the Outlook section [2]. Group 2: Approval and Review - The amended MD&A documents have been reviewed by the Company's Audit Committee and approved by the Board of Directors as of September 12, 2024 [4]. Group 3: Company Overview - XORTX is a pharmaceutical company focused on developing therapies for progressive kidney disease, with two clinically advanced products: XRx008 for ADPKD and XRx-101 for acute kidney injury related to COVID-19 [5]. - The Company also has a pre-clinical program, XRx-225, targeting Type 2 Diabetic Nephropathy, and aims to improve patient quality of life through innovative treatments [5].
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A